Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1411-1417

  Kabbinavar, Fairooz ^a   Fehrenbacher, Louis ^b   Hainsworth, John ^c   Kasubhai, Saifuddin ^d   Kressel, Bruce ^e   Marsland, Thomas ^f   Patel, Taral ^g   Rubin, Mark ^h   White, Leonard ⁱ   Yang, James Chih Hsin ^j   Klughammer, Barbara ^k   Colburn, Dawn ^l   Miller, Vincent ^m   Johnson, Bruce E ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d Northwest Medical Specialties   (United States)

^e Sibley Memorial Hospital   (United States)

^f Integrated Community Oncology Network   (United States)

^g Mark H Zangmeister Center   (United States)

^h Florida Cancer Specialists   (United States)

ⁱ Center for Cancer Care and Research   (United States)

^j NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l GENENTECH INC   (United States)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Bevacizumab; Biomarkers; Erlotinib; Maintenance; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PACLITAXEL; PLACEBO; TUMOR MARKER; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ONCOGENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT HISTORY OF RADIOTHERAPY; PATIENT HISTORY OF SURGERY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; WILD TYPE; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; EPIDEMIOLOGY; LUNG NEOPLASMS; METABOLISM; MORTALITY; MULTICENTER STUDY; TRENDS; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84906226358     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000274     Document Type: Article

References (15)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
4. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
7. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIb trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2013;31:3926-3934.
8. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113-4120.
9. Zhu CQ, da Cunha SG, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
10. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
11. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in nonsmall cell lung cancer on progression-free and overall survival: a metaanalysis. J Natl Cancer Inst 2013;105:595-605.
12. Soulieres D, Wolf J, Shepherd FA, et al. Meta-analysis of the predictive and prognostic values of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): recommendations of the BioLOGUE advisors (Abstract). J Clin Oncol 2011;29:7533.
13. Schneider CP, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008;3:1446-1453.
14. Metro G, Chiari R, Duranti S, et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer 2012;78:81-86.
15. Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-part 2). J Thorac Oncol 2012;7:1490-1502.